In situ RT-PCR detection of Epstein-Barr virus immediate-early transcripts in CD4+ and CD8+ T lymphocytes

Anticancer Research

Volumn 18, Issue 5 A, 1998, Pages 3171-3180

  Guan, Mingxu ^a   Romano, Gaetano ^a   Henderson, Earl E ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CDH+ and CD8+ T cell; Epstein Barr virus; Immediate early transcripts; In situ RT PCR

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN; VIRUS CAPSID ANTIGEN;

ARTICLE; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMEDIATE EARLY GENE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; VIRUS GENE;

ANTIGENS, VIRAL; BURKITT LYMPHOMA; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL NUCLEUS; DNA-BINDING PROTEINS; HERPESVIRUS 4, HUMAN; HUMANS; IMMEDIATE-EARLY PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; VIRAL PROTEINS;

EID: 0031731285     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Albrecht H, Schäfer H, Stellbrink HJ and Greton H: Epstein-Barr virus-associated hemophagocytic syndrome: a cause of fever of unknown origin in human immunodeficiency virus infection. Arch Pathol Lab Med 121: 853-858, 1997.
2. Baer R, Bankier AT, Biggin MD, Deininger PL, Farrell PJ, Gibson TJ, Hatfull G, Hudson GS, Satchwell SC, Séguin C, Tuffnell PS and Barrell BG: DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 310: 207-211, 1984.
3. Bagasra O, Hauptman SP, Lischner HW, Sachs M and Pomerantz RJ: Detection of human immunodeficiency virus type 1 provirus in mononuclear cells by in situ polymerase chain reaction. N Eng J Med 326: 1385-1391, 1992.
4. Brielmeier M, Mantner J, Laux G and Hammerschmidt W: The latent membrane protein 2 gene of Epstein-Barr virus is important for efficient B cell immortalization. J Gen Virol 77: 2807-2818, 1996.
5. Brooks L, Yao QY, Rickinson AB and Young LS: Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol 66: 2689-2697, 1992.
6. Casareale D, Sinangil F, Hedenskog M, Ward W, Volsky D and Sommebend J: Establishment of retrovirus, Epstein-Barr virus-positive B lymphoblastoid cell lines derived from individuals at risk for acquired immune deficiency syndrome (AIDS). AIDS Res 1: 253-270, 1983.
7. Chen CL, Sadler RH, Walling DM, Su IJ, Hsieh HC, and Raab-Traub N: Epstein-Barr virus (EBV) gene expression in EBV-positive peripheral T-cell lymphomas. J Virol 67: 6303-6308, 1993.
8. Cheng AL, Su IJ, Chen YC, Uen WC and Wang CH: Characteristic clinicopathologic features of Epstein-Barr virus-associated peripheral T-cell lymphoma. Cancer 72: 909-916, 1993.
9. Chevallier-Greco A, Gruffat H, Manet E, Calender A and Sergeant A: The Epstein-Barr virus (EBV) DR enhancer contains two functionally different domains: domain A is constitutive and cell specific, domain B is transactivated by the EBV early protein R. J Virol 63: 615-623, 1989.
10. Chevallier-Greco A, Manet E, Chavrier P, Mosnier C, Daillie J and Sergeant A: Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter. EMBO J 5: 3243-3249, 1986.
11. Countryman J and Miller G: Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc Natl Acad Sci USA 82: 4085-4089, 1985.
12. Epstein MA, Achong BG and Barr YM: Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet i: 702-703, 1964.
13. Farrell PJ, Rowe DT, Rooney MC and Kouzarides T: Epstein-Barr virus BZLF1 transactivator specifically binds to a consensus AP1 site and is related to c-fos. EMBO J 8: 127-132, 1989.
14. Giot JF, Mikaelian I, Buisson M, Manet E, Joab I, Nicolas JC and Sergeant A: Transcriptional interference between the EBV transcription factors EB1 and R: both DNA-binding and activation domains of EB1 are required. Nucleic Acids Res 19: 1251-1258, 1991.
15. Gruffat H, Duran N, Buisson M, Wild F, Buckland R and Sergeant A: Characterization of an R-binding site mediating the R-induced activation of the Epstein-Barr virus BMLF1 promoter. J Virol 66: 46-52, 1992.
16. Guan MX, Romano G and Henderson EE: Epstein-Barr virus (EBV)-induced long-term proliferation of CD4-positive lymphocytes leading to T lymphoblastoid cell lines carrying EBV. In preparation.
17. + T lymphocytes by Epstein-Barr virus enhances human immunodeficiency virus expression. J Virol 70: 7341-7346, 1996.
18. Hardwick JM, Lieberman PM and Hayward SD: A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J Virol 62: 2274-2284, 1988.
19. Henderson EE, Yang JY, Zhang RD and Bealer M: Altered HIV expression and EBV-induced transformation in coinfected PBLs and PBL subpopulations. Virology 182: 186-198, 1991.
20. Katsuki T, Hinuma Y, Saito T, Yamamoto J, Hirashima Y, Sudoh H, Deguchi M and Motokawa M: Simultaneous presence of EBNA-positive and colony-forming cells in peripheral blood of patients with infectious mononucleosis. Int J Cancer 23: 746-750, 1979.
21. Kenney S, Kamine J, Holley-Guthrie E, Lin JC, Mar EC and Pagano J: The Epstein-Barr virus (EBV) BZLF1 immediate-early gene product differentially affects latent versus productive EBV promoters. J Virol 63: 1729-1736, 1989.
22. Kenney S, Kamine J, Holley-Guthrie E, Mar EC, Lin JC, Markovitz D and Pagano J: The Epstein-Barr virus immediate-early gene product, BMLF1, acts in trans by a posttranscriptional mechanism which is reporter gene dependent. J Virol 63: 3870-3877, 1989.
23. Kenney S, Kamine J, Markovitz D, Fenrick R and Pagano J: An Epstein-Barr virus immediate-early gene product trans-activates gene expression from the human immunodeficiency virus long terminal repeat. Proc Natl Acad Sci USA 85: 1652-1656, 1988.
24. Kikata H, Taguchi Y, Tommizawa K, Kojima K, Kawamura N, Ishizaka A, Sakiyama Y, Matsumoto S, Imai S, Kinoshita T, Koizumi S, Osato T, Kobayashi I, Hamada I and Hirai K: Epstein-Barr virus genome-positive T lymphocytes in a boy with chronic active EBV infection associated with Kawasaki-like disease. Nature 333: 455-457, 1988.
25. Klein G, Svedmyr E, Jondal M and Persson PO: EBV-determined nuclear antigen (EBNA)-positive cells in the peripheral blood of infectious mononucleosis patients. Int J Cancer 17: 21-26, 1976.
26. Lieberman PM, O'Hare P, Hayward GS and Hayward D: Promiscuous trans-activation of gene expression by an Epstein-Barr virus-encoded early nuclear protein. J Virol 60: 140-148, 1986.
27. Miller CL, Burkhardt AL, Lee J H, Stealey B, Longnecker R, Bolen JB and Kieff E: Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity 91: 772-776, 1995.
28. 28a Miller CL, Lee JH, Kieff E and Longnecker R: An integral membrane protein (LMP2) blocks reactivation of immunoglobulin crosslinking. Proc Natl Acad Sci USA 91: 772-776, 1994.
29. 28b Makamura H, Iwakiri D, Ono Y and Fujiwara S: Epstein-Barr-virus-infected human T-cell line with a unique pattern of viral-gene expression. Int J Cancer 76: 587-594, 1998.
30. Paterson RLK, Kelleher C, Amankonah TD, Streib JE, Xu JW, Jones JF and Gelfand EW: Model of Epstein-Barr virus infection of human thymocytes: expression of viral genome and impact on cellular receptor expression in the T-lymphoblastic cell line, HPB-ALL Blood 85: 456-464, 1995.
31. Pfitzner AJ, Strominger JL and Speck SH: Characterization of a cDNA clone corresponding to a transcript from the Epstein-Barr virus BamHI M fragment: evidence for overlapping mRNAs. J Virol 61: 2943-2946, 1987.
32. Planz O, Seiler P, Hengartner H and Zinkernagel RM: Speciffc cytotoxic T cells eliminate cells producing neutralizing antibodies. Nature 382: 726-729, 1996.
33. Quinlivan EB, Holley-Guthrie E, Mar EC, Smith MS and Kenney S: The Epstein-Barr virus BRLF1 immediate-early gene product transactivates the human immunodeficiency virus type 1 long terminal repeat by a mechanism which is enhancer independent. J Virol 64: 1817-1820, 1990.
34. Sixby JW, Nedrud JG, Raab-Traub M, Hanes RA and Pagano JS: Epstein-Barr virus replication in oropharyngeal epithelial cells. N Eng J Med 310: 1225-1230, 1984.
35. Starr SE: Novel mechanism of immunosuppression after measles. Lancet 348: 1257-1258, 1996.
36. Stevenson M, Volsky B, Hedenskog M and Volsky DJ: Immortalization of human T lymphocytes after transfection of Epstein-Barr virus DNA. Science 233: 980-984, 1986.
37. Svedmyr E, Ernberg I, Seeley J, Weiland O, Masucci G, Tsukuda K, Szigeti R, Masucci MG, Blomgren H, Berthold W, Henle W and Klein G: Virologic, immunologic, and clinical observations on a patient during the incubation, acute, and convalescent phases of infectious mononucleosis. Clin Immunol Immunopathol 30: 437-450, 1984.
38. Thomas JA, Cotter F, Hanby AM, Long LQ, Morgan PR, Bramble B and Bailey BM: Epstein-Barr virus-related oral T-cell lymphoma associated with human immunodeficiency virus immunosuppression. Blood 81: 3350-3356, 1993.
39. Tierney RJ, Steven N, Young LS and Rickinson AB: Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol 68: 7374-7385, 1994.
40. Titti F, Borsetti A, Federico M, Testa U, Meccia E, Samoggia P, Peschie C, Verani P and Rossi GB: Extrachromosomal human immunodeficiency virus type 1 DNA forms in fresh peripheral blood lymphocytes and in two interleukin-2-independent T cell lines derived from peripheral blood lymphocytes of an asymptomatic seropositive subject. J Gen Virol 73: 3087-3097, 1992.
41. Todd SC and Tsoukas CD: EBV induces proliferation of immature human thymocytes in an IL-2-mediated response. J Immunol 156: 4217-4223, 1996.
42. Yoneda N, Tatsumi E, Kawanishi M, Teshigawara K, Masuda S, Yamamura Y, Inui A, Yoshino G, Oimomi M, Baba S and Yamaguchi N: Detection of Epstein-Barr virus genome in benign polyclonal proliferative T cells of a young male patient. Blood 76: 172-177, 1990.
43. Watry D, Hedrick JA, Siervo S, Rhodes G, Lamberti JJ, Lambris JD and Tsoukas CD: Infection of human thymocytes by Epstein-Barr virus. J Exp Med 173: 971-980, 1991.
44. Wong KM and Levine AJ: Identification and mapping of Epstein-Barr virus early antigens and demonstration of a viral gene activator that functions in trans. J Virol 60: 149-156, 1986.
45. Wong KM and Levine AJ: Characterization of proteins encoded by the Epstein-Barr virus transactivator gene BMLF1. Virology 168: 101-111, 1989.
46. Zhang RD, Guan M, Park Y, Tawadros R, Yang JY, Gold B, Wu B and Henderson EE: Synergy between human immunodeficiency virus type 1 and Epstein-Barr virus in T lymphoblastoid cell lines. AIDS Res Hum Retrovir 13: 161-171, 1997.
47. Millot F, Brizard F, Babin P, Canioni D, Macintyre E, Levard G, Gambert C, Ricour C and Guilhot F: t(3;17)(q21;q25) in Epstein-Barr virus associated peripheral T-cell lymphoma: a paediatric case. Br J Haematol 100: 331-334, 1998.
48. Hanson MN, Morrison VA, Peterson BA, Stieglbauer KT, Kubic VL, McCormick SR, McGlennen RC, Manivel JC, Brunning RD and Litz CE: Posttransplant T-cell lymphoproliferative disorder an aggressive, late complication of solid-organ transplantation. Blood 88: 3626-3333, 1996.
49. Kanegane H, Bhatia K, Gutierrez M, Kaneda H, Wada T, Yachie A, Seki H, Arai T, Kagimoto S, Okazaki M, Oh-ishi T, Moghaddam A, Wang F and Tosato G: A syndrome of peripheral blood T-cell infection with Epstein-Barr virus (EBV) followed by EBV-positive T-cell lymphoma. Blood 91: 2085-2091, 1998.
50. Steinitz M and Klein G: Comparison between growth characteristics of an Epstein-Barr virus (EBV)-genome-negative lymphoma line and its EBV-converted subline in vitro. Proc Natl Acad Sci USA 72: 3518-3520, 1975.
51. Smith SD, Shatsky M, Cohen PS, Warnke R, Link MP and Glader BE: Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines. Cancer Res 44: 5657-5660, 1984.